MedTrace Logo

Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers

NCT04729309 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2024-07-15

Study results available
· View outcomes & findings →

Summary

The objective of this study is to characterize the mass balance, absolute bioavailability, route and rates of elimination of RO7049839.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[12C] RO7049389

Participants will receive oral \[12C\] RO7049389.

DRUG

[13C] RO7049389

Participants will receive IV \[13C\] RO7049389.

DRUG

[14C] RO7049389

Participants will receive an oral suspension of \[14C\] RO7049389.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2021-06-14
Completion
2021-06-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04729309 on ClinicalTrials.gov